Neuphoria Therapeutics (NEUP) Expected to Post Earnings on Monday

Posted by George Bondi on Oct 3rd, 2026

Neuphoria Therapeutics (NASDAQ:NEUP – Get Free Report) is projected to announce its Q4 2026 results before the market opens on Monday, October 5th. Analysts expect the company to announce earnings of ($1.58) per share for the quarter. Individuals can check the company’s upcoming Q4 2026 earning report for the latest details on the call scheduled for Friday, September 18, 2026 at 7:00 AM ET.

Neuphoria Therapeutics Trading Down 1.1%

Shares of NASDAQ NEUP opened at $3.47 on Friday. The firm has a 50 day moving average of $3.78 and a 200 day moving average of $4.25. The firm has a market capitalization of $18.77 million, a price-to-earnings ratio of -0.56 and a beta of 0.75. Neuphoria Therapeutics has a 12-month low of $3.19 and a 12-month high of $21.40.

Analysts Set New Price Targets

NEUP has been the topic of several recent research reports. Wall Street Zen upgraded shares of Neuphoria Therapeutics to a “hold” rating in a research report on Saturday, July 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Neuphoria Therapeutics in a research note on Thursday, August 27th. Two equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Reduce” and an average target price of $7.00.

View Our Latest Report on Neuphoria Therapeutics

Neuphoria Therapeutics Company Profile

(Get Free Report)

Neuphoria Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for obesity and other metabolic diseases. The company’s research programs are designed to address conditions involving weight management, diabetes and metabolic dysfunction.

Neuphoria’s pipeline includes DA-1726, an investigational dual GLP-1 and glucagon receptor agonist being developed for obesity and related metabolic conditions. The company is also developing DA-1241, an investigational GPR119 agonist intended for metabolic dysfunction-associated steatohepatitis, formerly known as nonalcoholic steatohepatitis, and other metabolic disorders.